Adapalene And Benzoyl Peroxide Swab
Product Images NDC 69150-001

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Adapalene And Benzoyl Peroxide Swab (NDC 69150-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biomes Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Label (Adapalene And Benzoyl Peroxide Swab Label)

Label for Adapalene and Benzoyl Peroxide Swabs containing 0.1% adapalene and 2.5% benzoyl peroxide in a 1.2g swab for topical use only. The label includes Biomes Pharmaceuticals branding, directions for use, storage instructions, warnings, and a barcode. The product is manufactured and distributed by Biomes Pharmaceuticals, Lansing, MI.*

FDA Label Image

Adapalene (Structure Adapalene)

Chemical structure diagram depicting the molecular configuration of adapalene, the active ingredient in the adapalene and benzoyl peroxide swab by Biomes Pharmaceuticals.*

FDA Label Image

Benzoyl Peroxide (Structure Benzoyl Peroxide)

Chemical structure diagram of the active ingredient for adapalene and benzoyl peroxide swab, showing molecular composition with aromatic rings and ester functional groups.*

FDA Label Image

Study 3 (Study 3)

Data table titled 'Study 3' comparing Adapalene and Benzoyl Peroxide with a Vehicle across three outcome measures: IGA two grade improvement and clear or almost clear, inflammatory lesions mean absolute (percent) change, and non-inflammatory lesions mean absolute (percent) change, including sample sizes of 142 and 143 respectively.*

FDA Label Image

Table 1 (Table 1)

Table showing drug-related adverse events reported in clinical trials for adapalene and benzoyl peroxide swab versus vehicle after 12 weeks. It lists frequency percentages of events like dry skin, contact dermatitis, application site burning, irritation, and skin irritation among patients treated with the drug and those given vehicle, based on sample sizes of 564 and 489 respectively.*

FDA Label Image

Table 2 (Table 2)

A data table titled 'Incidence of Local Cutaneous Irritation in Controlled Clinical Trials (N = 553)' showing the maximum severity and end of treatment severity percentages for treatment emergent signs and symptoms including erythema, scaling, dryness, and stinging/burning. The table includes categories of mild, moderate, and severe over a 12-week treatment period.*

FDA Label Image

Table 3 (Table 3)

A data table titled 'Clinical Efficacy of Adapalene and Benzoyl Peroxide at Week 12' comparing results from two studies. The table reports efficacy outcomes for adapalene and benzoyl peroxide gel, adapalene 0.1% in vehicle gel, benzoyl peroxide 2.5% in vehicle gel, and vehicle gel only. Outcomes include two-grade improvement and clear or almost clear status by IGA, as well as mean absolute percent changes in inflammatory and non-inflammatory lesions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.